Skip to Main Content

Paper Details

Vandetanib Reduces Inflammatory Cytokines and Ameliorates COVID-19 in Infected Mice.
bioRxiv
1
2021
-, A549, A549-hACE2 cells, COVID-19, DBT, EGFR, HCoV-229E, IFN-1, IL-, IL-6, MHV, Mice, RET, SARS, SARS-, SARS-CoV, SARS-CoV-2, SARS-CoV-2 infection, SARS-CoV-2-infected Caco-2, TNF-, VEGFR, Vandetanib, baricitinib, delayed brain tumor, delayed brain tumor (DBT) cell line, dexamethasone, epidermal growth factor receptor, hACE2, hACE2 cells, inflammatory cell infiltrates, mice, mouse, murine hepatitis virus, remdesivir, tyrosine, tyrosine kinase, uninfected, vandetanib, vascular endothelial growth factor receptor, viral infection
Author NameAffiliation
Boyd L YountGillings School of Public Health, University of North Carolina at Chapel Hill
Ralph S BaricUniversity of North Carolina School of Medicine
Ralph S BaricUniversity of North Carolina at Chapel Hill
Ralph S BaricGillings School of Public Health, University of North Carolina at Chapel Hill
Ralph S BaricUniversity of North Carolina School of Medicine
Ralph S BaricUniversity of North Carolina at Chapel Hill
Ralph S BaricGillings School of Public Health, University of North Carolina at Chapel Hill
  • 1 - 7

Datasets

Release 1.2